MHC Ligandomes of Reovirus-Treated Tumors

Published: 23 April 2019| Version 2 | DOI: 10.17632/t5xb48z959.2
John Patrick Murphy


Using a mass spectrometry (MS)-based MHC-I ligandome discovery platform, we determined differential tumor MHC-I ligand expression following treatment with oncolytic reovirus in a murine ovarian cancer model. We then tested the immunogenicity and antitumor immune effects of CD8 T cells specific to these reovirus-induced ligands.